OTCMKTS:IPSEY IPSEN (IPSEY) Stock Price, News & Analysis $32.22 0.00 (0.00%) As of 08/1/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendHeadlinesShort InterestBuy This Stock About IPSEN Stock (OTCMKTS:IPSEY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IPSEN alerts:Sign Up Key Stats Today's Range$32.22▼$32.2250-Day Range$28.94▼$33.0052-Week Range$25.11▼$33.00Volume153 shsAverage Volume433 shsMarket Capitalization$10.80 billionP/E RatioN/ADividend Yield0.81%Price TargetN/AConsensus RatingBuy Company Overview Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France. Read More Receive IPSEY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IPSEN and its competitors with MarketBeat's FREE daily newsletter. Email Address IPSEY Stock News HeadlinesIpsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)July 31, 2025 | globenewswire.comCabometyx® approved in the EU for previously treated advanced neuroendocrine tumorsJuly 24, 2025 | theglobeandmail.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world. | Traders Agency (Ad)Ipsen - Half year statement - 2025 06 30 - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comIpsen S.A. (IPSEY) stock price, news, quote & history - Yahoo FinanceJune 26, 2025 | au.finance.yahoo.comIpsen Pharma: Ipsen receives positive CHMP opinion for Cabometyx in previously treated advanced neuroendocrine tumorsJune 20, 2025 | finanznachrichten.deIpsen S.A. - Initiation of the share buy-back programJune 2, 2025 | globenewswire.comIpsen S.A. - Annual General Meeting held on 21 May 2025May 21, 2025 | globenewswire.comSee More Headlines IPSEY Stock Analysis - Frequently Asked Questions How have IPSEY shares performed this year? IPSEN's stock was trading at $28.97 at the beginning of 2025. Since then, IPSEY shares have increased by 11.2% and is now trading at $32.22. How do I buy shares of IPSEN? Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Ex-Dividend for 6/25 Dividend6/09/2025Record date for 6/25 Dividend6/10/2025Dividend Payable6/25/2025Today8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryN/A Current SymbolOTCMKTS:IPSEY CIKN/A Webwww.ipsen.com Phone(315) 833-5000Fax33-01-58-33-50-01Employees5,358Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.34 Quick Ratio1.15 Sales & Book Value Annual Sales$3.87 billion Price / Sales2.79 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares335,260,000Free FloatN/AMarket Cap$10.80 billion OptionableNot Optionable Beta0.50 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (OTCMKTS:IPSEY) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IPSEN Please log in to your account or sign up in order to add this asset to your watchlist. Share IPSEN With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.